These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 12422564)

  • 21. Valproate-induced encephalopathy.
    Rehman A; Zafar S
    J Coll Physicians Surg Pak; 2005 Sep; 15(9):571-2. PubMed ID: 16181582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Valproate and babies.
    Whitehall J; Smith J
    Aust N Z J Psychiatry; 2008 Sep; 42(9):837. PubMed ID: 18696289
    [No Abstract]   [Full Text] [Related]  

  • 23. Safety and efficacy of intravenous sodium valproate in the treatment of acute migraine.
    Waberzinek G; Marková J; Mastík J
    Neuro Endocrinol Lett; 2007 Feb; 28(1):59-64. PubMed ID: 17277725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Valproate-associated hyperammonemic encephalopathy. Report of one case].
    Young P; Finn BC; Alvarez F; Bruetman JE; Trimarchi H
    Rev Med Chil; 2007 Nov; 135(11):1446-9. PubMed ID: 18259656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reversible dementia and gait disturbance after prolonged use of valproic acid.
    Evans MD; Shinar R; Yaari R
    Seizure; 2011 Jul; 20(6):509-11. PubMed ID: 21435910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Valproate-associated coagulopathies are frequent and variable in children.
    Attilakos A; Katsarou E; Voudris K; Garoufi A
    Epilepsia; 2007 Jan; 48(1):205-6. PubMed ID: 17241231
    [No Abstract]   [Full Text] [Related]  

  • 27. Valproate-induced systemic lupus erythematous: A case report.
    Boussaadani Soubai R; Lahlou M; Tahiri L; Rabhi S; Harzy T; Bono W
    Rev Neurol (Paris); 2013 Mar; 169(3):278-9. PubMed ID: 23522291
    [No Abstract]   [Full Text] [Related]  

  • 28. Spasmodic dysphonia induced by valproic acid.
    Oh J; Park KD; Cho HJ; Choi KG; Jung SM
    Epilepsia; 2004 Jul; 45(7):880-1. PubMed ID: 15230719
    [No Abstract]   [Full Text] [Related]  

  • 29. Prolonged use of phenytoin, carbamazepine or valproate monotherapy on plasma levels of folate and B(12): a comparison between epileptic patients with or without cardiovascular disorders.
    Otoom S; Bakhiet M; Khan A; Sequeira R
    Neuro Endocrinol Lett; 2006; 27(1-2):85-8. PubMed ID: 16648782
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Dementia and extrapyramidal problems caused by long-term valproic acid].
    Masmoudi K; Gras-Champel V; Bonnet I; Pannier M; Masson H; Rosa A; Andréjak M
    Therapie; 2000; 55(5):629-34. PubMed ID: 11201978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Cognitive impairment and parkinsonism due to use of sodium valproate].
    Schreur L; Middeljans-Tijssen CW; Hengstman GJ; Olde Rikkert MG
    Tijdschr Gerontol Geriatr; 2009 Feb; 40(1):29-33. PubMed ID: 19326700
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Valproate-induced reversible hemichorea.
    Srinivasan S; Lok AW
    Mov Disord; 2010 Jul; 25(10):1511-2. PubMed ID: 20629154
    [No Abstract]   [Full Text] [Related]  

  • 33. A case of valproate-induced hyperammonemic encephalopathy: look beyond the liver.
    Alqahtani S; Federico P; Myers RP
    CMAJ; 2007 Sep; 177(6):568-9. PubMed ID: 17846437
    [No Abstract]   [Full Text] [Related]  

  • 34. [Reversible dementia due to valproic acid therapy].
    Walstra GJ
    Ned Tijdschr Geneeskd; 1997 Feb; 141(8):391-3. PubMed ID: 9157301
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phenytoin-induced parkinsonism.
    Ertan S; Ulu MO; Hanimoglu H; Tanriverdi T; Kafadar AM; Acar ZU; Kiziltan G
    Singapore Med J; 2006 Nov; 47(11):981-3. PubMed ID: 17075669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Acute Intermittent porphyria and valproic acid].
    Noval Menéndez J; Campoamor MT; Laborda B; López-Colina G
    Rev Clin Esp; 2012 Apr; 212(4):217-8. PubMed ID: 22112281
    [No Abstract]   [Full Text] [Related]  

  • 37. [Treatment with valproate and hepatic steatosis].
    Ortiz-Sáenz de Santa María R; Santiago-Fernández C; Cano-Del Pozo M; Pérez-Gil O; Soto-Alvarez MI; Barriuso-Pérez E; Moche-Loeri JA
    Rev Neurol; 2005 Dec 16-31; 41(12):766-7. PubMed ID: 16355364
    [No Abstract]   [Full Text] [Related]  

  • 38. Different clinical manifestations of hyperammonemic encephalopathy.
    Gomceli YB; Kutlu G; Cavdar L; Sanivar F; Inan LE
    Epilepsy Behav; 2007 Jun; 10(4):583-7. PubMed ID: 17412645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Valproate-induced hyperacute hyperammonemic coma in a patient with hypocarnitinemia.
    Sofi A; Herial NA; Ali II
    Am J Ther; 2013; 20(6):e703-5. PubMed ID: 20224318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reversible parkinsonism induced by prolonged treatment with valproate.
    Onofrj M; Thomas A; Paci C
    J Neurol; 1998 Dec; 245(12):794-6. PubMed ID: 9840351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.